Signal Desk · Companies

Biocon’s Pebrilzo gets first EMA tailored-pathway biosimilar approval

2026-11-18 · 1 source · BusinessLine Companies

In short

Biocon’s Pebrilzo became the first biosimilar approved under the EMA’s tailored clinical pathway. The approval is being called a regulatory milestone for the company.

It also adds to Biocon’s oncology biosimilars portfolio in Europe and the United States. That can support the company’s wider cancer drug push in those markets.

What the reporting says

Biocon’s Pebrilzo became the first biosimilar approved under the EMA’s tailored clinical pathway, according to a publisher-supplied company summary. The approval is described as a regulatory milestone for Biocon and as an expansion of its oncology biosimilars portfolio in Europe and the United States.

Why it matters

Biocon’s Pebrilzo became the first biosimilar approved under the EMA’s tailored clinical pathway. The approval is described as a regulatory milestone and as part of Biocon’s growing oncology biosimilars portfolio in Europe and the United States, supporting its position in cancer drugs in those markets.

Touches: Biocon, Healthcare, Companies

Sources